Clinical Research Directory

Inclusion Criteria: 1. Signed and dated written informed consent. 2. Adult (≥18 years) at the time of consent 3. Established T2D diagnosis as per Diabetes Canada 4. HbA1c ≤10.0% 5. eGFR ≥45 ml/min/1.73m2 6. BP ≤160/90 and ≥90/60 mmHg 7. BMI 18.5-45.0 kg/m2 8. On stable dose of maximally tolerated RAASi for ≥30 days Exclusion Criteria: 1. Established diagnosis of type 1 diabetes as per Diabetes Canada 2. With known or suspected hypersensitivity or allergy to acetazolamide, dapagliflozin or related products 3. Iodine intolerance 4. Untreated urinary or genital tract infection 5. Serum potassium \<3.5 mmol/L 6. Serum bicarbonate \<22 mEq/L 7. Use of carbonic anhydrase inhibitor in the 30 days prior to screening 8. Liver disease (hepatic cirrhosis, alcohol/drug abuse ≥3 months, or serum AST, ALT, or total bilirubin \>3X the upper limit of normal) 9. Severe glaucoma 10. Acute coronary syndrome, stroke or transient ischemic attack within 30 days prior to screening 11. Active pregnancy, breastfeeding or planning to become pregnant during study period 12. Participation in another drug trial within 30 days of screening 13. Patient not able to understand and comply with study requirements, based on Investigator's judgment. 14. Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome